Aprea Therapeutics Determines RP2D Of 1,100 Mg Once Daily For ATRN-119, Oral ATR Inhibitor In Monotherapy Arm Of Ongoing ABOYA-119 Phase 1/2a Dose-Escalation Study, In Patients With Advanced Solid Tumors.

Author: Benzinga Newsdesk | October 15, 2025 08:04am

• ATRN-119 (ATR Inhibitor): RP2D of 1,100 mg once daily identified in ongoing ABOYA-119 dose-escalation study
• Further ATRN-119 monotherapy enrollment paused with strategic focus on high-value combination
• Company is prioritizing its lead program, WEE1 kinase inhibitor APR-1051
   

DOYLESTOWN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that it has determined the recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119, its oral ATR inhibitor in the monotherapy arm of the ongoing ABOYA-119 Phase 1/2a dose-escalation study, in patients with advanced solid tumors.

Posted In: APRE